Xortx TherapeuticsXRTX
13F holders, Q2 2026 (June 30)6holders +4
5new positions
1sold out
1famous investor
$2.30avg. 13F price*
At the end of Q2 2026, 6 institutions reported holding Xortx Therapeutics Inc. (XRTX) in their 13F filings, up 4 from Q1 2026. 5 opened new positions and 1 sold out. The largest holders were Citadel Advisors ($52K), StoneX Group Inc. ($38K) and Royal Bank of Canada ($2K). One famous investor held it Ken Griffin (0.0% of Citadel Advisors's portfolio).
- Company
- Xortx Therapeutics Inc.
- CUSIP
- 98420Q405
- Latest filing quarter
- Q2 2026
History
Number of 13F holders
Total Exit/New Position Q1 2026 → Q2 2026
| Institutions | Total Value | |
|---|---|---|
| New Positions | 5 | $93K |
| Exits | 1 | $6K |
All 13F filers, Q1 2026 → Q2 2026: 40,388 shares bought and 15,222 shares sold, net +25,166 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 6 holders
| Citadel Advisors | 0.00% | New | 23,116 | $52K |
| StoneX Group Inc. | 0.00% | New | 16,369 | $38K |
| Royal Bank of Canada | 0.00% | New | 732 | $2K |
| National Bank of Canada | 0.00% | New | 162 | $329 |
| Clearstead Advisors, LLC | 0.00% | Reduce -80.1% | 55 | $120 |
| TD Waterhouse Canada Inc. | 0.00% | New | 9 | $19 |
"% of holder's portfolio" is XRTX's weight in each manager's 13F, not the share of Xortx Therapeutics Inc. the manager owns.